This week's biggest news for IPF patients is that an AI system, after searching thousands of drug combinations, found a mix that kept simulated lung function at nearly 98% — a result researchers haven't seen before.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
Our database now holds over 6,200 IPF studies and nearly 1,650 clinical trials (real experiments with people). Most exciting recent work focuses on how fibrosis (scarring) starts at the cell level, with strong research coming from Russia, China, and Korea alongside major preprint (early, not yet fully reviewed) publications. No IPF-specific papers landed in the very latest batch, but the field keeps growing fast.
The AI tested drug combinations and the best result kept FVC (a measure of how much air your lungs can hold) at 98.3% — basically near-normal. That is remarkable. The winning mix included 7 drugs targeting scarring signals, lung cell repair, and inflammation all at once. This is still computer modelling, not a pill you can take today, but it points scientists toward real experiments next.
One question to ask your lung doctor at your next visit: 'Are there any combination drug trials open right now that I might qualify for?'